sCD163 in PBC Patients - Assessment of Treatment Response

Recruiting now

Conditions studied: Primary Biliary Cirrhosis, Liver Inflammation, Ursodeoxycholic Acid

In brief

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.

Key facts

Study ID

NCT02931513

Run by

University of Aarhus

People needed

40

Starts

2016-09-01

Expected to finish

2031-09-01

Last updated by the study team

2022-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed with Primary biliary cholangitis
• No treatment with UDCA

You may not qualify if…

• Patient under 18 years
• Expected lifetime under 6 months
• Expected liver transplantation within 6 months
• Liver cancer
• Cirrhosis from other causes

Where it is running

• Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark — Aarhus C, Central Jutland, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.